Published in:
Open Access
01-12-2015 | Letter
The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
Authors:
François Bertucci, Pascal Finetti, Daniel Birnbaum
Published in:
Breast Cancer Research
|
Issue 1/2015
Login to get access
Excerpt
We read with interest the article by Khaleel and colleagues reporting a new prognostic signature in hormone receptor (HR)-positive breast cancer based on mRNA expression of target genes of the E2F4 transcription factor [
1]. The clinical relevance comes from its independent prognostic value and its biological significance (mainly regulation of cell cycle and proliferation, reflecting high E2F4 activity). When compared with patients with low score for the signature (low risk), patients with high score (high risk) showed shorter relapse-free survival, making them candidates for adjuvant chemotherapy. Whereas adjuvant chemotherapy is recommended for most human epidermal growth factor receptor 2 (HER2)-positive or triple-negative tumors, indications are more challenging for HR
+/HER2
− tumors, which are candidates for either adjuvant hormone therapy alone or both hormone therapy and chemotherapy. …